(2,5-Dioxopyrrolidin-1-yl) 2-[[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]acetate | 796865-55-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: (2,5-Dioxopyrrolidin-1-yl) 2-[[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]acetate
• CAS: 796865-55-9
• 化学式: C₂₀H₂₆N₄O₁₁
• 分子量: 498.447
• InChiKey: NKFQYAHADQWSMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  35
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  186
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 iminodiacetic acid 在 4-二甲氨基吡啶 、 N,N'-二异丙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以68%的产率得到(2,5-Dioxopyrrolidin-1-yl) 2-[[2-(2,5-dioxopyrrolidin-1-yl)oxy-2-oxoethyl]-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]acetate
  参考文献：
  名称：

  含有促红细胞生成素模拟肽的药物组合物

  摘要：

  本发明涉及含有促红细胞生成素模拟肽的药物组合物，其还含有10%～15%重量的表面活性剂、10%～15%重量的稳定剂、42%～46%重量的等渗调节剂和16～20%重量的缓冲液。本发明的有益效果是针对特定的促红细胞生成素模拟肽筛选出特定的药用辅料得到稳定的药物组合物。

  公开号：

  CN103536900B

文献信息

• NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES
  申请人：Holmes Christopher P.

  公开号：US20090048147A1

  公开（公告）日：2009-02-19

  The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: wherein α, β, and γ are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein κ, ρ, and τ are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein χ, φ, γ, and η are each integers whose values are independently selected. Alternatively, the linker structure may have the following structure: wherein λ and μ are each integers whose values are independently selected.

  本发明涉及一种化合物，包括肽基团、连接基团和水溶性聚合物基团，例如聚乙二醇基团。连接基团位于肽基团和水溶性聚合物基团之间。在某些实施例中，连接基团具有以下结构：其中α、β和γ分别是独立选择的整数。在其他实施例中，连接基团具有以下结构：其中κ、ρ和τ分别是独立选择的整数。在其他实施例中，连接基团具有以下结构：其中χ、φ、γ和η分别是独立选择的整数。或者，连接结构也可以具有以下结构：其中λ和μ分别是独立选择的整数。
• WO2006/133144
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2007/70372
  申请人：——

  公开号：——

  公开（公告）日：——
• Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds
  申请人：Holmes P. Christopher

  公开号：US20070032408A1

  公开（公告）日：2007-02-08

  The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure: —NH—(CH 2 ) α —[O—(CH 2 ) β ] γ —O δ —(CH 2 ) ε —Y— wherein α, β, γ, δ, and ε are each integers whose values are independently selected.
• Erythropoietin receptor peptide formulations and uses
  申请人：Duliege Anne-Marie

  公开号：US20070104704A1

  公开（公告）日：2007-05-10

  The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.